Quarterly Outlook
Q4 Outlook for Investors: Diversify like it’s 2025 – don’t fall for déjà vu
Jacob Falkencrone
Global Head of Investment Strategy
Investment and Options Strategist
Summary: As Novo Nordisk prepares to release its Q3 earnings report, a focus on its game-changing obesity care treatments has propelled the stock into the limelight. With a forecasted 27% YoY revenue growth and EBITDA of DKK 27bn, the stakes are high. This article explores four curated options strategies to fit bullish, bearish, and neutral stances on Novo Nordisk.